Clinigen Group plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Clinigen Group plc
Deal Watch: Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
US FDA’s Non-Cancer Accelerated Approval Drugs Get Their Own Public Databases
Accelerated Approval Program web page links to searchable databases for accelerated approvals of infectious disease products, vaccines, and other nonmalignant indications. New databases, which include products that converted to regular approval or were withdrawn, are modeled after Oncology Center of Excellence’s cancer drug databases that debuted in 2021.
Keeping Track: US FDA Approval Of Jazz Rylaze Addresses Shortage; MediWound, Cyclopharm Receive CRLs
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Zydus Cadila Joins IO Therapy League With XOMA Tie-up
Cadila Healthcare has entered the immuno-oncology race by inking a licensing agreement with US-based XOMA for a drug candidate that combines the Indian firm's interleukin-2 with the latter’s novel anti-IL-2 monoclonal antibody
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Clinigen KK
- CSM Parent
- Idis Group Holdings Limited
- IDIS Pharma
- International Medical Management Corporation
- iQone Healthcare
- Link Healthcare
- Quantum Pharma plc
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.